Protara R&D chief sells 1,134 company shares

Protara Therapeutics, Inc. Chief R&D Officer Jacqueline Zummo sold 1,134 shares of Common Stock on April 8, 2026 at $5.40 per share in an open-market transaction.

Accepted by SEC EDGAR 04/09/2026 - 05:25 PM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Protara Therapeutics, Inc. Chief R&D Officer Jacqueline Zummo sold 1,134 shares of Common Stock on April 8, 2026 at $5.40 per share in an open-market transaction. The sale occurred automatically under a Rule 10b5-1 trading plan established on December 31, 2025. Following the sale, she directly holds 94,827 shares.

Insider Trade Summary

Net Seller: 1,134 shares

Net Sell 1 txn

Insider Zummo Jacqueline

Role Chief R&D Officer

Sold 1,134 shs ($6K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,134	$5.40	$6K

Holdings After Transaction: Common Stock — 94,827 shares (Direct)

Footnotes (1)

F1. The sale reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan established by the reporting person on December 31, 2025.

Key Figures

Shares sold: 1,134 shares Sale price per share: $5.40 per share Shares owned after transaction: 94,827 shares +1 more

4 metrics

Shares sold 1,134 shares Open-market sale on April 8, 2026

Sale price per share $5.40 per share Common Stock transaction price

Shares owned after transaction 94,827 shares Direct holdings following April 8, 2026 sale

Rule 10b5-1 plan date December 31, 2025 Date trading plan was established

Key Terms

Rule 10b5-1 trading plan, open-market sale, Common Stock

3 terms

Rule 10b5-1 trading plan regulatory

"occurred automatically pursuant to a Rule 10b5-1 trading plan established by the reporting person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

""security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Protara Therapeutics (TARA) report for Jacqueline Zummo?

Protara Therapeutics reported that Chief R&D Officer Jacqueline Zummo sold 1,134 shares of Common Stock. The open-market sale occurred on April 8, 2026 at a price of $5.40 per share and was executed under a pre-arranged Rule 10b5-1 trading plan.

At what price were the Protara Therapeutics (TARA) shares sold in this Form 4?

The reported sale of Protara Therapeutics Common Stock was executed at $5.40 per share. This reflects the transaction price for the 1,134 shares sold on April 8, 2026 in an open-market transaction disclosed in the Form 4 filing for Jacqueline Zummo.

How many Protara Therapeutics (TARA) shares does Jacqueline Zummo hold after the sale?

After the reported transaction, Chief R&D Officer Jacqueline Zummo directly holds 94,827 shares of Protara Therapeutics Common Stock. This post-transaction ownership figure comes from the Form 4 and reflects her direct holdings immediately following the April 8, 2026 sale.

Was the Protara Therapeutics (TARA) insider sale made under a Rule 10b5-1 trading plan?

Yes. The Form 4 footnote states the sale occurred automatically pursuant to a Rule 10b5-1 trading plan. That plan was established by Jacqueline Zummo on December 31, 2025, indicating the transaction was pre-arranged rather than initiated on the trade date.

Who is the insider involved in the latest Protara Therapeutics (TARA) Form 4 filing?

The insider is Jacqueline Zummo, Chief R&D Officer of Protara Therapeutics, Inc. She reported an open-market sale of 1,134 shares of the company’s Common Stock at $5.40 per share on April 8, 2026, under a pre-established Rule 10b5-1 plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zummo Jacqueline

(Last)

(First)

(Middle)

C/O PROTARA THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, 3RD FLOOR

(Street)

NEW YORK

10010

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Protara Therapeutics, Inc. [ TARA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief R&D Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/08/2026		S		1,134⁽¹⁾	D	$5.4	94,827	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sale reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan established by the reporting person on December 31, 2025.

Remarks:

	/s/ Jacqueline Zummo	04/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR